David Woodhouse arrived at Nuvig Therapeutics at a moment that rewards restraint. The company already had a large Series B behind it, a clinical-stage lead program in motion, and a technology platform capable of producing more possibilities than a small organization could sensibly pursue. This is the dangerous abundance of biotechnology: many promising directions, finite people, finite time, finite capital. The chief executive's task is to turn possibility into sequence.
Woodhouse has been preparing for that job through a career that refuses to stay in one lane. He learned the grammar of the laboratory, then the arithmetic of the capital markets, then the slower and less forgiving craft of operating a research company. His biography can be read as a series of changes - scientist, banker, CFO, CEO - but the subject never really changed. At every stop, he was working on the same problem: how a scientific idea earns the resources and evidence required to become something larger.
He became Nuvig's chief executive and a board director in September 2025. Founder and chief scientific officer Pamela Conley described his approach as systematic and pointed to his experience across life sciences, finance, and business development. Woodhouse's own first message emphasized rigorous science, the team, and a clear opportunity. The nouns were revealing. He was joining neither a spreadsheet nor a single molecule. He was joining a system.
The useful hybrid
Woodhouse studied pharmacology at the University of California, Santa Barbara, graduating with highest honors. He earned a doctorate in molecular pharmacology at Stanford's medical school and later an MBA from Dartmouth's Tuck School. The combination can sound over-designed in retrospect, like a resume built by committee. In practice, it gave him three ways to interrogate the same proposal. Is the biology coherent? Is the strategy legible? Is the financing durable?
Early roles at Amgen and Dynavax kept him close to research and business development. In 2002, he moved to Goldman Sachs. He stayed for 13 years, eventually becoming a managing director in healthcare investment banking and co-head of U.S. biotechnology investment banking. The numbers attached to that period are large: several billion dollars in equity and equity-linked financings, plus more than $90 billion in merger and acquisition advice across biotechnology, specialty pharmaceutical, and diagnostics companies.
Banking offers a privileged view of other people's turning points. You see the data room, the pitch, the negotiation, and the moment a market decides what it will fund. You do not necessarily live through the years after the announcement. Woodhouse crossed that boundary in March 2015, when he left Goldman to become chief financial officer of NGM Biopharmaceuticals.
The timing mattered. NGM was expanding its research organization around a broad collaboration with Merck. As CFO, Woodhouse moved from advising on capital to being accountable for what capital could buy. Three and a half years later, he was promoted to chief executive and joined the board. The appointment was connected directly to NGM's planned transition into a public company. His financial training had brought him inside; his knowledge of the people, platform, and pipeline helped put him in charge.
“I am thrilled to join Nuvig at such an important stage in the company's development.”David J. Woodhouse, September 2025
The market is a clock
NGM began trading on Nasdaq in April 2019. Its initial public offering generated $107.8 million net, while a concurrent private placement with Merck added $65.9 million. Together, the transactions put $173.7 million of net cash behind the company's research and development plans. A public listing also installed a visible clock. Each quarter made the distance between spending and evidence easier for outsiders to measure.
Woodhouse's NGM tenure was not a tidy ascent. Few serious biotechnology careers are. The company advanced multiple clinical programs and maintained major partnerships, but it also had to narrow priorities as evidence, capital, and market conditions changed. In 2023, management described a more concentrated development strategy and plans to seek partners for programs outside its chosen focus. Portfolio discipline sounds bloodless from a distance. Inside a research culture, it means telling smart people that a plausible idea will not be the next idea funded.
Fund the next proof, not the entire dream.
Woodhouse's public operating themes center on financing to the next value inflection, building relevant evidence early, and using explicit milestones so partners and teams share a definition of progress.
In April 2024, NGM returned to private ownership through an acquisition by affiliates of The Column Group. The public-to-private arc compressed a full market education into five years. An IPO gives a company currency and attention. Private ownership can give it a different time horizon. Neither structure makes the biology move faster. Each changes who bears the risk, how progress is narrated, and when patience runs out.
Several months after going private, NGM announced a $122 million financing to support two clinical programs. That event made the transition concrete: a narrower plan, a new capital base, and milestones selected for the next phase. Woodhouse had now experienced biotechnology from both sides of the listing ceremony. The lesson available to Nuvig is not that public or private is inherently better. It is that ownership structure must serve the proof the company needs to generate.
A platform meets a sequence
Nuvig was founded before Woodhouse arrived. Its founders had already built the scientific premise, advanced its lead candidate into clinical development, and raised a $161 million Series B in December 2024. By the time he took the CEO role, the company was no longer asking whether it could begin. It was asking how to allocate momentum.
That is a distinct leadership handoff. Founding energy expands the map. Operating discipline chooses a route through it. Nuvig's platform is designed to create precisely engineered immunomodulators, giving the company both a lead program and a source of future programs. The abundance is strategically valuable only if management can decide what to advance internally, what to partner, what evidence to gather first, and what to leave alone.
Woodhouse has spoken publicly about disciplined financing, payer-relevant evidence, shared quality metrics with outside partners, and decision rules that keep teams moving together. These are plain phrases, almost aggressively so. They become interesting when applied to a real calendar. A decision rule made before results arrive can protect a team from explaining away inconvenient data. A financing tied to a specific proof point can reduce dilution without starving the work. An early view of future evidence requirements can prevent a technically successful study from answering the wrong commercial question.
Boardroom peripheral vision
Woodhouse also chairs Surrozen's board. He joined that board in September 2020 and became chair in April 2023. The position supplies a useful second camera angle. A CEO works deep inside one company's choices. A board chair must step back, test the frame, and judge whether management is solving the right problem. Holding both perspectives can sharpen the difference between activity and progress.
His appointment to Surrozen originally emphasized the same hybrid that later attracted Nuvig: scientific training paired with finance and leadership experience. Woodhouse said then that he looked forward to helping develop a pipeline that captured the potential of the company's platform. Five years later, his job at Nuvig carries a similar sentence with direct accountability attached.
The recurring word in his career is platform. Platforms create option value, and option value is intoxicating. Every additional program can be presented as another chance to win. Yet a small biotechnology company is defined as much by the work it declines as by the work it starts. The chief executive has to preserve imagination without letting optionality become an excuse for diffusion.
Make the decision rule before the decision gets emotional.
A portfolio stays coherent when milestones, quality measures, and stopping points are explicit. The rule is a promise that evidence will outrank attachment.
What the next proof demands
Woodhouse's aspiration at Nuvig is direct: advance the lead program through its current studies and use the broader platform to create additional treatments. The statement is conventional. The preparation behind it is not. He has seen how a molecule is discussed at a laboratory bench, how the same molecule is valued in a financing, how it is ranked in a portfolio review, and how its progress is explained to public shareholders.
That range does not guarantee the result of an experiment. It improves the quality of the sequence around the experiment. It helps a company ask what must be true before it spends the next dollar, what evidence a partner will need, and how much organizational attention one program can absorb. In a sector built on uncertainty, those questions are among the few controllable variables.
The most useful way to read Woodhouse's path is as accumulated accountability. Research taught him to respect mechanism. Banking taught him to see capital as conditional. The CFO role made resource allocation immediate. The CEO role made every tradeoff cultural as well as financial. Board leadership added distance. Nuvig is where those lessons now meet.
A biotech company can tell an enormous story years before it can deliver a decisive answer. Woodhouse's career suggests a quieter operating philosophy: define the next answer, finance it properly, and build the team around getting it. Then earn the right to ask the larger question.